NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
NantKwest (NASDAQ: NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be making multiple presentations associated with the company’s off-the-shelf CD16 targeted NK cell (hanK) and NANT Cancer Vaccine platform at the upcoming Society for Immunotherapy of Cancer (SITC) Conference which runs from November 7 – 11 in Washington D.C.
SITC Conference Details:
First in human data in advanced solid tumors of NANT Cancer Vaccine: A novel temporospatial orchestration of the innate (NK) & adaptive immune system to induce antigen cascade & immunogenic cell death
|Session:||Immune Escape: Currently Understanding of Mechanisms and Advances in Therapeutics Approaches|
|Date/Time:||Wednesday, November 7, 2018, 5:45pm EST|
NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater metastatic pancreatic cancer
|Date:||Friday, November 9, 2018|
|Type:||Poster Presentation/Abstract #P713|
NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater TNBC and head & neck cancer
|Date:||Saturday, November 10, 2018|
|Type:||Poster Presentation/Abstract #P310|
About NantKwest Inc.
NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The NantKwest “off-the-shelf” activated Natural Killer (NK) platform has the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell-based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying the Company will be successful in improving the treatment of cancer. Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of our NK cells as well as other therapeutics as part of the NANT Cancer Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105006066/en/